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Alzheimer’s disease (AD) is characterized by
amyloid-b (Ab) and tau deposition in brain. It has
emerged that Ab toxicity is tau dependent, although
mechanistically this link remains unclear. Here, we
show that tau, known as axonal protein, has
a dendritic function in postsynaptic targeting of the
Src kinase Fyn, a substrate of which is the NMDA
receptor (NR). Missorting of tau in transgenic mice
expressing truncated tau (Dtau) and absence of tau
in tau/ mice both disrupt postsynaptic targeting
of Fyn. This uncouples NR-mediated excitotoxicity
and hence mitigates Ab toxicity. Dtau expression
and tau deficiency prevent memory deficits and
improve survival in Ab-forming APP23 mice, a model
of AD. These deficits are also fully rescued with
a peptide that uncouples the Fyn-mediated interac-
tion of NR and PSD-95 in vivo. Our findings suggest
that this dendritic role of tau confers Ab toxicity at
the postsynapse with direct implications for patho-
genesis and treatment of AD.
INTRODUCTION
Alzheimer’s disease (AD) is characterized by two hallmark
lesions, amyloid-b (Ab) plaques and neurofibrillary tangles
(NFTs) (Ballatore et al., 2007). Ab is derived from the amyloid-b
precursor protein (APP) by proteolytic cleavage (Haass et al.,
1992; Selkoe, 1997). The major constituent of NFTs is tau,
a microtubule (MT)-associated protein (Goedert et al., 1988). In
the course of AD, tau becomes phosphorylated, forming aggre-
gates that deposit as NFTs and neuropil threads (Geschwind,
2003). Tau can also form aggregates in the absence of an overt
Ab pathology, for example in frontotemporal dementia (FTD),where familial mutations have been identified in the tau-encod-
ing MAPT gene (Ballatore et al., 2007). Evidence that tau
pathology in AD is induced by Ab comes from our previous
observation that intracerebral Ab injections exacerbate hyper-
phosphorylation of tau and NFT formation in transgenic mice
that express FTDmutant P301L tau (Go¨tz et al., 2001b). A similar
finding was obtained by crossing transgenic mice with NFT and
plaque pathologies (Lewis et al., 2001).
Ab-plaque formation along with memory impairment and tau
pathology with increased phosphorylation, in the absence of
deposition and NFT formation, has been reproduced in several
transgenic mouse lines that express human APP together with
pathogenic mutations identified in familial AD (Go¨tz and Ittner,
2008; Hsiao et al., 1996; Mucke et al., 2000; Sturchler-Pierrat
et al., 1997). In one of these, PDAPP, tau deficiency (tau/)
was shown to rescue lethality andmemory deficits by an uniden-
tified mechanism (Roberson et al., 2007).
Tau is known as axonal protein that regulates MT stability
and MT-dependent processes (Dixit et al., 2008; Drechsel
et al., 1992; Lee et al., 1988), while Ab likely exerts toxicity
at the postsynapse (Selkoe, 2002; Shankar et al., 2008;
Zhao et al., 2006). Although in AD, hyperphosphorylated tau
accumulates in the somatodendritic compartment of neurons
(Ballatore et al., 2007), given the spatial separation it remains
unknown how tau is involved in mediating Ab toxicity when AD
is initiated.
Seizures characterize several APP transgenic strains (Minkevi-
ciene et al., 2009; Palop et al., 2007; Palop andMucke, 2009) and
have been associated with AD; the extent of their contribution to
pathology, however, remains to be established (Minkeviciene
et al., 2009; Palop et al., 2007; Palop and Mucke, 2009). Excito-
toxicity results from overactivation of N-methyl-D-aspartate
(NMDA) receptors (NRs). Interestingly, tau reduction decreases
susceptibility to excitotoxic seizures in vivo, which may explain
the concomitant improvement of the PDAPP phenotype (Rober-
son et al., 2007). How tau prevents excitotoxic damage at
a molecular level is not understood.Cell 142, 387–397, August 6, 2010 ª2010 Elsevier Inc. 387
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Figure 1. Truncated Tau Is Excluded from
Dendrites in Dtau74 Mice
(A) The longest human tau isoform (htau40; 441 aa)
is composed of an amino-terminal projection
domain (PD), the microtubule-binding (MTB)
domain with four repeats (gray boxes), and the car-
boxy-terminal tail (C0). Dtau transgenic mice
express only the PD of tau under control of the
neuronal mThy1.2 promoter. Dtau lacks the MTB
domain and therefore the MT-binding and aggre-
gation properties of full-length tau, but contains
a Fyn binding site.
(B) Expression pattern of Dtau in Dtau74 brains.
Immunohistochemistry (IHC) with a human tau-
specific antibody (HT7; brown) reveals Dtau
expression within several brain regions, including
hippocampus (hp), cortex (cx), and amygdala (am).
(C) Western blotting of wild-type and Dtau74
hippocampal extracts reveals endogenous murine
tau (50 kD) in all andDtau (37 kD) only in transgenic
samples. Quantification shows comparable levels
of endogenous tau, while endogenous tau and
Dtau levels add up to 2.4-fold increased total levels
in Dtau74 compared to WT mice.
(D) IHC of the hippocampal CA1 region reveals that inDtau74mice,Dtau localizes to the soma (S) but is excluded fromdendrites (D), whereas expression of P301L
mutant full-length tau in pR5 mice results in a somato-dendritic localization of transgenic tau (HT7; reactive with Dtau and pR5 tau, but not endogenous tau,
in red). The scale bar represents 50 mm.
Error bars represent the standard error. See also Figure S1.Tau interacts via its amino-terminal projection domain (PD)
with the kinase Fyn (Figure 1A) (Lee et al., 1998). Fyn phosphor-
ylates the NR subunit 2 (NR2) to facilitate interaction of the NR
complex with the postsynaptic density protein 95 (PSD-95)
(Nakazawa et al., 2001; Rong et al., 2001; Tezuka et al., 1999),
linking NRs to synaptic excitotoxic downstream signaling (Salter
and Kalia, 2004). Disruption of the NR/PSD-95 interaction
prevents excitotoxic damage in cultured neurons and a rat
model of stroke, without affecting synaptic NMDA currents
(Aarts et al., 2002). Reduction of Fyn in APP transgenic mice
prevents Ab toxicity, while overexpression enhances it (Chin
et al., 2005; Chin et al., 2004).
To address how tau confers Ab toxicity, we generated trans-
genic mice (Dtau74) that express only the amino-terminal projec-
tion domain (PD) of tau and crossed them with Ab-forming
APP23 and tau/ mice. We found that tau has an important
dendritic function, as in Dtau74 and tau/ mice, postsynaptic
Fyn localization is reduced, resulting in reduced NR phosphory-
lation, destabilized NR/PSD-95 interaction, and protection from
excitotoxicity.
RESULTS
Truncated Tau Is Excluded from Dendrites
Tau comprises an amino-terminal projection domain, an MT
binding (MTB) domain that mediates interaction with MTs
(Butner and Kirschner, 1991; Lee et al., 1988) and is essential
for tau aggregation (Crowther et al., 1989; Ksiezak-Reding and
Yen, 1991) and a carboxy-terminal tail region (Figure 1A). We
generated truncated (Dtau) transgenic mice that express the
projection domain of tau in neurons, intended to compete with
functions of endogenous tau. Four phenotypically normal lines388 Cell 142, 387–397, August 6, 2010 ª2010 Elsevier Inc.expressed Dtau throughout the brain (Figure 1B) at comparable
levels, with line Dtau74 expressing the transgene at 1.4-fold
higher levels than endogenous tau (Figure 1C). Expression of
Dtau neither affected levels nor distribution of endogenous tau
(Figure 1C and Figures S1A–S1C available online). Consistent
with previous in vitro findings (Maas et al., 2000), Dtau localized
to the cell membrane, as indicated by coimmunostaining with
cadherin and subcellular fractionation of membranes (Figures
S1D and S1E). In AD and also full-length P301Lmutant tau trans-
genic pR5 mice, tau is hyperphosphorylated and redistributed
into the somatodendritic compartment (Figure 1D) (Go¨tz et al.,
2001a). In contrast to full-length tau, Dtau, while in the soma,
was virtually excluded from dendrites (Figure 1D). In pR5
mice, tau becomes progressively hyperphosphorylated and
insoluble, and eventually the mice develop NFTs. Surprisingly,
Dtau in Dtau74 mice is hardly phosphorylated at all (Figure S1F).
Postsynaptic Targeting of Fyn Is Tau Dependent
Different from full-length human tau in pR5 mice, in the absence
of anMTB domain,Dtau fails to interact with MTs, as determined
byMT precipitation from hippocampi (Figure 2A). However, Dtau
contains motifs that mediate interaction with the Src kinase Fyn,
as shown in vitro (Lee et al., 1998). Accordingly, Fyn can be coim-
munoprecipitated with Dtau from Dtau74 hippocampi in vivo,
using a human tau-specific antibody (HT7) (Figure 2B). Immuno-
precipitation (IP) with tau-specific antibodies to epitopes not
present on the Dtau construct reveals a significantly reduced
interaction of Fyn with endogenous tau (Figure 2B). Likewise,
IP with Fyn antibodies shows a reduced interaction with endog-
enous tau in Dtau74 mice (Figure 2B). Together, this suggests
a dominant negative effect of Dtau on the normal interaction of
Fyn and endogenous tau. A similar effect on the Fyn/Tau
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Figure 2. Dtau Impairs Tau-Dependent
Dendritic Targeting of the Src Kinase Fyn
(A) Dtau from Dtau74 mice does not interact with
microtubules. Endogenous murine tau, but not
Dtau, precipitates with microtubules in extracts
from Dtau74 mice. In contrast, both full-length
human and endogenous murine tau precipitate
with microtubules in extracts from pR5 mice.
(B) Expression of Dtau results in a 74% ± 6%
(n = 8; *p < 0.01) reduced interaction of Fyn with
endogenous murine tau (mtau) compared to the
wild-type (wt), as revealed by coimmunoprecipita-
tion (coIP) with antibodies to endogenous murine
tau (mTau). In Dtau74 mice, Fyn instead coimmu-
noprecipitates with Dtau, as revealed by antibody
HT7. Similarly, in pR5 mice, Fyn precipitates with
full-length human tau (htau). CoIP with Fyn anti-
bodies predominantly pulled down endogenous
tau in WT, Dtau in Dtau74, and full-length human
tau in pR5 mice. No precipitation was observed
from tau/ tissue.
(C) Fyn accumulates in cell bodies in Dtau74,
tau/, andDtau74.tau/mice.While Fyn staining
(red) colocalizes with dendritic drebrin (green) in
WT CA1 neurons, Fyn staining is evident in the
soma (S) and is reduced in the dendrites (D) of
Dtau74 and tau/ neurons. The insets show
higher magnification of dendritic staining. The
scale bar represents 50 mm.
(D) Quantification of fluorescence intensity of Fyn
staining in cell bodies and dendrites shows accu-
mulation of Fyn in cell bodies of Dtau74, tau/,
and Dtau74.tau/ mice (n = 15, *p < 0.0001).
(E) Total Fyn levels are not reduced in Dtau74 and
tau/ mice. Western blots of hippocampal
extracts from WT, Dtau74, and tau/ brains
show comparable levels of Fyn, normalized to
Gapdh (n = 6).
(F) Phosphorylation of activating (Y420) and inactivating (Y531) sites of immunopurified Fyn from WT, Dtau74, and tau/ brains is similar.
(G) Hippocampal synaptosomal preparations reveal reduced levels of Fyn in Dtau74 and tau/ postsynapses compared to the WT (n = 6, *p < 0.005).
Error bars represent the standard error. See also Figure S2.interaction was obtained by overexpression of full-length tau in
pR5 mice (Figure 2B). Given the dendritic exclusion of Dtau in
Dtau74 in contrast to full-length tau in pR5 mice (Figure 1D),
we speculated that the aberrant Dtau/Fyn interaction might
affect the normal intracellular distribution of Fyn. Immunohisto-
chemistry showed that Fyn colocalized with drebrin in wild-
type (WT) brain, consistent with postsynaptic targeting, while in
Dtau74 brains it accumulated in the soma, an effect enhanced
by crossing of Dtau and tau/ (Figures 2C and 2D). Together
with reduced dendritic Fyn staining, this suggests impaired
postsynaptic targeting of Fyn. To determine the role of tau in
dendritic localization of Fyn, we also analyzed tau/ mice. Fyn
also accumulated in the soma (Figures 2C and 2D), suggesting
that postsynaptic targeting of Fyn is, at least in part, tau depen-
dent. This is consistent with reduced localization of Fyn-DsRED
in primary hippocampal neurons either from tau/ mice or mice
coexpressingDtau (Figure S2). Interestingly, further truncation of
Dtau shows that the Fyn-interactive motif, PXXP (Lee et al.,
1998), is critical for Fyn localization.
Despite changes in the localization of Fyn, its total levels
and activity were comparable in Dtau74, tau/, and WT mice,as determined by total and phosphorylation site-specific anti-
Fyn antibodies (Figures 2E and 2F). To quantify changes in the
subcellular localization of Fyn, we prepared synaptosomes
from WT, Dtau74, and tau/ hippocampi. Consistent with the
immunohistochemical findings of reduced postsynaptic target-
ing, levels of synaptic Fyn were reduced by 73% and 62% in
Dtau74 and tau/ mice, respectively, compared to WT controls
(Figure 2G). Taken together, both the presence of Dtau and
absence of endogenous tau impair synaptic localization of Fyn.
Uncoupled NMDA Receptors and PSD-95 in Dtau
and tau/ Synapses
The postsynaptic NR subunit NR2b is a known substrate of
Fyn (Nakazawa et al., 2001). NR2b phosphorylation at Y1472
strengthens the NR/PSD-95 interaction (Rong et al., 2001). In
both Dtau74 and tau/ mice, Y1472 phosphorylation is signifi-
cantly reduced compared to the WT, while total levels of NR1,
NR2a, and NR2b are unaffected (Figure 3A). To determine
whether this affects the stability of NR/PSD-95 complexes,
we performed coimmunoprecipitations (coIPs). Markedly less
NR1, NR2a, and NR2b coimmunoprecipitated with PSD-95Cell 142, 387–397, August 6, 2010 ª2010 Elsevier Inc. 389
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Figure 3. Destabilized NMDA Receptors in
the Postsynaptic Density of Dtau74 and
tau/ Mice
(A) Levels of NR subunits NR1, NR2a and NR2b,
and PSD-95 are comparable in extracts from WT,
Dtau74, and tau/ brains, whereas phosphoryla-
tion of NR2b at the Fyn site, Y1472, that is known
to stabilize NR/PSD-95 complexes (Roche et al.,
2001), is significantly reduced in Dtau74 and
tau/ than in the WT (n = 6, *p < 0.005).
(B) PSD-95 antibodies coimmunoprecipitate much
less NR subunits NR1, NR2a, and NR2b from
Dtau74 and tau/ than from WT hippocampi.
Similarly, coimmunoprecipitation (coIP) of Fyn
with PSD-95 is reduced in Dtau74 and tau/
compared to WT hippocampi, while that of nNOS
and Homer was unaffected. Endogenous murine
Tau (mTau) coprecipitates with PSD-95 from WT
hippocampi, while much less mTau, but no Dtau
(HT7), is recovered from Dtau74 hippocampi.
mTau is absent in tau/ coIPs, consistent with
tau deficiency. (n = 3, *p < 0.005.)
(C) Sequential extraction of synaptosomes. Puri-
fied WT synaptosomes were further fractionated
with buffers of increasing stringency (pH6 <
pH8 < SDS), to purify proteins that are stably asso-
ciated with the PSD (Phillips et al., 2001). Brain
extracts (total) are loaded for comparison. NR
subunits NR1, NR2a and NR2b, PSD-95, tau,
and Fyn are purified in the SDS fraction, consistent
with strong anchoring in the PSD. Soluble proteins,
such as GAP43 and proteins that are not (such as
SNAP25) or less stably associated with the PSD,
are extracted with less stringent pH 6 and pH 8
buffers, respectively.
(D) SDS fractions from synaptosomes show that
stable anchoring of NRs in the PSD is reduced in
Dtau74 and tau/ mice. While NRs are recovered
in the SDS fraction of WT synaptosomes, they are
primarily found in the pH 8 and hardly at all in SDS
fractions from Dtau74 and tau/ mice.
(E) Representative traces of AMPAR- (gray) and
NR- (black) mediated components of electrically
evoked (e) EPSCs in CA1 hippocampal neurons from WT, Dtau74, tau/, and Dtau74.tau/ mice (average of 12 sweeps per neuron) normalized with AMPAR-
mediated component. Neurons were voltage clamped and held at +40 mV. AMPAR-mediated eEPSCs are inverted for clarity. There is no significant difference of
NMDA/AMPA ratios between genotypes (n = 19–20).
(F) Representative traces of eEPSCs (average of 12 sweeps per neuron) separating total NMDAR-mediated and NR2b subunit-mediated components
(black traces, total NR eEPSC minus component in CP-101,606 [5 mM]) normalized to the amplitude of the total NR eEPSC. Neurons were voltage clamped
at +20 mV. NR2b EPSCs were obtained by subtraction of EPSCs generated in CP101 606 (5 mM) from total NR-mediated EPSCs, i.e., before CP applications.
There is no significant difference in the percentage of NR2b component between genotypes (n = 18–20).
(G and H) Mean amplitude (G) and rate (s1) (H) of AMPAR-mediated mEPSCs (recorded in 1 mMTTX) were unaffected in Dtau74, tau/, and Dtau74.tau/mice
(n = 10–12).
Error bars represent the standard error. See also Figure S3.from Dtau74 and tau/ compared to WT extracts, consistent
with a decreased interaction of NR and PSD-95 in both strains
(Figure 3B). The PSD-95-interacting proteins Homer and
nNOS, however, were coimmunoprecipitated to a similar extent
from WT, Dtau74, and tau/ brains, suggesting intact interac-
tions. The NR/PSD-95 interaction facilitates stable anchoring
of NRs in the postsynaptic density (PSD) (Roche et al., 2001).
Therefore, we next extracted purified synaptosomes from WT,
Dtau74, and tau/mice that show similar levels of NR subunits,
but reduced NR2b phosphorylation at Y1472 (Figure S3A), using390 Cell 142, 387–397, August 6, 2010 ª2010 Elsevier Inc.buffers of increasing stringency (Phillips et al., 2001). In line with
a strong PSD association in WT synaptosomes, NR subunits
were mostly found in the SDS fraction (Figure 3C and 3D). In
contrast, they were markedly reduced in Dtau74 and tau/,
appearing instead in earlier fractions, suggestive of a weakened
anchoring in the PSD (Figure 3D). Interestingly, endogenous
tau that was enriched by synaptosome preparation, recovered
in WT SDS fractions and coimmunoprecipitated with PSD-95
from WT, and to a lesser degree from Dtau74, brains (Figures
3B and 3C and Figure S1C).
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Figure 4. Dtau Expression Improves
Memory and Ameliorates Premature
Mortality of APP23 Mice
(A) APPswe transgenic APP23mice (n = 76) present
with a pronounced premature mortality that is
ameliorated by reducing tau levels in APP23.tau+/
(n = 41, p < 0.001) and even more in APP23.tau/
mice (n = 108, p < 0.0001). Expression of Dtau
improves the survival of APP23.Dtau74 mice
(orange, n = 43, p < 0.01) similar to APP23.tau+/.
Interestingly, combination of Dtau expression with
tau reduction completely rescues APP23.Dtau74.-
tau+/ (purple, n = 38, p < 0.0001) and
APP23.Dtau74.tau/ (red, n = 52, p < 0.0001)
mice from lethality.
(B) Improved memory acquisition of APP23.D
tau74, APP23.tau/, and APP23.Dtau74.tau/
compared to APP23 mice in the T maze, 2 and 24
hr after a five-trial acquisition, at 8 months of age.
While WT, Dtau74, and tau/ mice only make few
errors during the trials, memory deficits of APP23
mice are obvious from the continuously high
numbers of errors made during the entire test. In
contrast, both APP23.Dtau74, APP23.tau/, and
APP23.Dtau74.tau/ mice presented with WT-
like numbers of errors (n = 8, *p < 0.05, **p < 0.01).
(C) In synaptosomal preparations obtained from 4-month-old APP23, both Fyn levels and NR2b phosphorylation at Y1472 are increased as compared to wild-
type (wt) mice (n = 6, *p < 0.05). However, in synaptosomes from APP23.Dtau74 and APP23.tau/, and even more in APP23.Dtau74.tau/, both levels of Fyn
and NR2b phosphorylation are significantly lower than in APP23 mice (n = 6, *p < 0.05, **p < 0.01). Representative western blots from three independent exper-
iments are shown.
(D–G) Dtau expression and tau deficiency do not affect APP mRNA expression, Ab levels, or plaque burden.
(D) Levels of APP mRNA are not altered in APP23 mice in the presence of Dtau or when tau is absent (tau/).
(E) Ab1–40 and Ab1–42 levels are comparable in APP23, APP23.Dtau74, and APP23.tau
/ mice.
(F and G) Thioflavine S staining (green) reveals Ab plaques (arrows; insets) at similar numbers (F) and with similar morphology (G) in APP23 mice, independent of
coexpression of Dtau or tau reduction.
Error bars represent the standard error. See also Figure S4.The organization of NRs within the PSD is important for coor-
dinated signal transduction (Kim and Sheng, 2004). Hence, alter-
ations of NRs in Dtau74 and tau/ mice may affect synaptic
currents. Therefore, we determined excitatory postsynaptic
currents (ESPCs) in acute hippocampal slices from WT,
Dtau74, tau/, and Dtau74.tau/ mice. In Dtau74, tau/,
and Dtau74.tau/ mice, we found np significant changes in
synaptic currents (Figure 3E). Similarly, no significant reduction
emerged in the contribution of NR2b-containing NRs to ESPCs
in Dtau74, tau/, and Dtau74.tau/ mice (Figure 3F). Baseline
miniature amplitudes and frequency were also comparable
(Figures 3G and 3H and Figures S3B–S3D). Taken together,
these data indicate that both expression ofDtau or tau deficiency
reduces the interaction of NRs with PSD-95 without affecting
synaptic NR levels and currents.
Dtau Expression Prevents Premature Lethality
and Memory Deficits in APP23 Mice
It has been shown previously that perturbing the interaction of
NRs with PSD-95 had no effect on NR-mediated currents but
reduced the resilience of neurons to NMDA-mediated excitotox-
icity (Aarts et al., 2002). Interestingly, excitotoxicity has been
proposed to contribute to Ab toxicity in PDAPP mice, which
was reduced when the mice were crossed onto a tau/ back-
ground (Roberson et al., 2007). APP expression per se maycontribute to toxicity in mice; however, primary disease-related
effects are attributed to Ab, as suggested by reverted deficits
in Ab-immunized APPmodels (Ro¨skam et al., 2010) and absence
of seizure-induced hippocampal remodeling in APP transgenic
mice with low Ab levels (Palop et al., 2007). Excitotoxicity has
been linked to premature lethality in APP transgenic mice (Chis-
hti et al., 2001; El Khoury et al., 2007; Leissring et al., 2003;
Roberson et al., 2007). Hence, we speculated that in Dtau74
alterations in NR/PSD-95 interaction might similarly rescue the
early lethality that characterizes APPswe mutant APP23 mice
(Figures S4A and S4B) (Sturchler-Pierrat et al., 1997). APP23
mice have high Ab levels already at a very young age (Kuo
et al., 2001; Van Dam et al., 2003), eventually forming plaques
and presenting with neuronal loss and memory deficits (Calhoun
et al., 1998; Kelly et al., 2003; Sturchler-Pierrat et al., 1997).
When we crossed APP23 either with Dtau74 or tau/ mice
(Figure S4C), this caused both a significantly delayed onset of
mortality and an improved overall survival (Figure 4A). Whereas
any rescue (either on a tau/ background or by expressing
Dtau) was partial, expression of Dtau on a heterozygous or
homozygous tau-deficient background rescued lethality
completely, suggesting complementary beneficial effects of
tau deficiency and Dtau expression on survival (Figure 4A).
In contrast, crossing of APP23 mice with pR5 mice with an
increased dendritic accumulation of tau (Figure 1D) (Go¨tz et al.,Cell 142, 387–397, August 6, 2010 ª2010 Elsevier Inc. 391
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Figure 5. Dtau Expression Reduces Susceptibility to Excitotoxic
Seizures
(A) When excitotoxic seizures were induced by i.p. injection of PTZ (50 mg/kg),
mean seizure severity was significantly reduced in both Dtau74, tau/, and
Dtau74.tau/ compared to WT mice (n = 10, **p < 0.01, ***p < 0.001).
(B) Similarly, the latency to more severe seizure stages is increased in Dtau74,
tau/, and Dtau74.tau/ mice.
(C) In APP23 mice, PTZ-induced seizures are mostly lethal (10 of 11), whereas
in APP23.Dtau74, APP23.tau/, and APP23.Dtau74.tau/ seizure severity is
markedly reduced (n = 10, *p < 0.05, **p < 0.01, ***p < 0.001).
(D) APP23.Dtau74, APP23.tau/, and APP23.Dtau74.tau/ mice show an
increased latency to more severe seizures compared to APP23 mice.
(E and F) Pretreatment of WT or APP23 mice with MK801 (0.1 mg/kg) reduced
seizure severity (n = 8, p < 0.05) (E) and increased latency to more severe
seizures (F).
Error bars represent the standard error.2001a), resulted in increased premature lethality, with no survival
beyond 4 months of age (Figure S4D). Interestingly, both Fyn
levels and Y1472 phosphorylation of NR2b are increased in
pR5 synaptosomes (Figure S4E). Because of possible confound-
ing effects of APP overexpression and Ab formation in APP
mutant mouse strains, we used also primary neurons treated
with Ab, in the absence of APP overexpression, as a model. In
tau/ and Dtau74-expressing neurons, acute Ab toxicity was
markedly reduced (Figure S2E). Interestingly, deletion of the
Fyn-interacting motif, PXXP (Lee et al., 1998), from Dtau abro-
gated the protective effect.
We next determined whether Dtau expression or tau reduction
also improves memory functions in APP23 mice. Memory defi-
cits were both improved to WT levels in APP23.Dtau74
and APP23.tau/ mice using the water T maze (Figure 4B).
Consistent with the findings in Dtau and tau/ mice, both
synaptic Fyn levels and NR2b phosphorylation were reduced
in APP23.Dtau74 and APP23.tau/ and even more so in
APP23.Dtau74.tau/ synaptosomes, while they were increased
in APP23 compared to WT brains (Figure 4C). Interestingly, in
APP23 mice, neither Dtau expression nor tau reduction affected
humanAPPmessenger RNA (mRNA) levels (Figure 4D), Ab levels
(Figure 4E), or plaque burden (Figures 4F and 4G). Similarly,
phosphorylation of endogenous tau was comparable in APP23
and APP23.Dtau74 mice (data not shown). Taken together,
expression of Dtau in APP23 or crossing of APP23 with tau/
mice reduces Fyn-mediated NR2b phosphorylation, attenuates
premature mortality, and improves memory deficits without
changing Ab levels or plaque load.
Dtau Reduces Susceptibility to Excitotoxic Seizures
Ab-induced aberrant excitatory neuronal activity may contribute
to the deficits that characterize ADmousemodels (Busche et al.,
2008; Palop and Mucke, 2009). APP23 mice show spontaneous
seizures (Lalonde et al., 2005), similar to other APP transgenic
strains (Minkeviciene et al., 2009; Palop et al., 2007; Palop and
Mucke, 2009). Hence, reduced mortality of APP23.Dtau74 and
APP.tau/ mice may be related to a reduced susceptibility to
excitotoxic seizures. We therefore first induced convulsions in
Dtau74, tau/, Dtau74.tau/, and WT mice using the g-amino-
butyrate (GABA) antagonist pentylenetetrazole (PTZ). Seizure
severity was significantly reduced in Dtau74, tau/, and
Dtau74.tau/ compared to theWT (Figure 5A), while the latency
to develop severe convulsion increased (Figure 5B). Next, we
induced seizures in APP23, APP23.Dtau74, APP23.tau/, and
APP23.Dtau74.tau/ mice. APP23 mice presented with a
reduced convulsion latency and showed themost severe seizure
response, with the lowest survival rate (1/11) and all mice reach-
ing status epilepticus (n = 11) (Figure 5C). However, when APP
expression was combined with Dtau expression or tau defi-
ciency, this significantly decreased seizure severity, reduced
fatality, and increased convulsion latency (Figures 5C and 5D).
The double mutant Dtau74.tau/ prevented severe seizures
better thanDtau74 or tau/ alone, on bothWT and APP23 back-
grounds, in agreement with the survival data (Figure 4A). Inter-
estingly, we found a similar degree of protection from PTZ-
induced seizures as in Dtau74, tau/, APP23.Dtau74, or
APP23.tau/ mice when we pretreated WT and APP23 mice,392 Cell 142, 387–397, August 6, 2010 ª2010 Elsevier Inc.
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Figure 6. Peptide-Driven Uncoupling of the
NR/PSD-95 Interaction Reduces Ab Toxicity
and Improves Survival and Memory of
APP23 Mice
(A) Twenty-day-old primary cortical neurons were
pretreated with 100 nM Tat-NR2B9c peptide,
which disrupts the NR/PSD-95 interaction (Aarts
et al., 2002), prior to treatment with the toxins
NMDA, Ab, H2O2, and staurosporine. Twenty-
four hours after treatment, cell death was deter-
mined by propidium iodide (PI) uptake. Control
cells were pretreated with vehicle or 100 nM Tat-
NR2BAA (inactive peptide).
(B and C) Tat-NR2B9c (bottom row) significantly
reduces toxicity of NMDA and Ab to cortical
neurons, as indicated by lower numbers of PI-
positive cells (red; arrows) compared to pretreated
vehicle (top row) or Tat-NR2BAA (middle row)
controls. Nuclei were stained with Hoechst
(blue). Treatment with H2O2, staurosporine,
NMDA, Ab, or NMDA/Ab causes significant cell
death (#p < 0.005, ##p < 0.0001), which for
NMDA- and Ab-treated neurons is reduced by
pretreatment with Tat-NR2B9c, but not for H2O2-
and staurosporine-treated neurons (*p < 0.05,
**p < 0.01). One hundred cells each were counted
in three independent experiments. The scale bar
represents 25 mm.
(D) Immunoprecipitation (IP) with a PSD-95 antibody from hippocampus of WT mice that were i.c.v. infused with Tat-NR2B9c and Tat-NR2BAA for 1 week, and
from untreated WT, Dtau74, and tau/ mice. Less NRs were coimmunoprecipitated upon Tat-NR2B9c, but not Tat-NR2BAA treatment. The reduction was
comparable to Dtau74 and tau/ mice.
(E) One week of i.c.v. infusion of Tat-NR2B9c reduced PTZ-induced seizure severity significantly, compared to inactive Tat-NR2BAA (n = 10, *p < 0.01).
(F) APP23 mice treated with vehicle (artificial cerebrospinal fluid [aCSF]) alone or together with Tat-NR2B9c or Tat-NR2BAA, using osmotic mini pumps. DOB,
date of birth.
(G) Survival of APP23 mice upon i.c.v. delivery of Tat-NR2B9c (n = 17) is markedly improved compared to vehicle (aCSF)-treated (n = 11, p < 0.01) and Tat-
NR2BAA-treated (n = 9, p < 0.05) controls. Gray boxes indicate time of drug delivery from two consecutively implanted pumps.
(H) Tat-NR2B9c-treated APP23 mice showmarkedly improved memory functions at 4 and 8 months after initiating treatment, compared to aCSF-treated or age-
matched untreated APP23 mice (n = 8, n = 4 for aCSF, *p < 0.05, **p < 0.01).
Error bars represent the standard error.respectively, with the NR-antagonist MK801 (Figures 5E and 5F).
Hence, reduced susceptibility to excitotoxicity is consistent with
a reduced NR contribution and may contribute to reduced
mortality in APP23 mice in the presence of Dtau or absence of
endogenous tau.
Targeted Uncoupling of NR and PSD-95 Prevents
Premature Death and Memory Seficits in APP23 Mice
Provided that disturbed NR/PSD-95 complexes with a reduced
dendritic Fyn localization in Dtau74 and tau/ mice contribute
to improved memory functions and survival of APP23.Dtau74
and APP23.tau/ mice, targeted perturbation of the NR/PSD-
95 interaction, independent of tau or Fyn, should also decrease
Ab toxicity. Therefore, we treated primary cortical cultures with
the Tat-NR2B9c peptide composed of carboxy-terminal amino
acids of NR2b (including Y1472) fused to a HIV1-Tat peptide to
achieve cell membrane permeability (Figure 6A). Tat-NR2B9c
has been shown previously to protect fromNMDA-induced exci-
totoxicity (Aarts et al., 2002; Kornau et al., 1995). As a negative
control, we included Tat-NR2BAA in which critical amino acids
were replaced by alanine (Aarts et al., 2002; Kornau et al.,
1995). NMDA and Ab both induced pronounced cell death, while
a combined NMDA/Ab treatment did not further increase celldeath, consistent with shared signaling pathwaysmediating their
toxicity (Figures 6B and 6C). Cell death induced by NMDA and
Ab, both separate and in combination, was significantly reduced
by preincubation with Tat-NR2B9c, but not when induced by
hydrogen peroxide or staurosporine (Figures 6B and 6C). Tat-
NR2BAA had no protective effects. Hence, perturbing the NR/
PSD-95 interaction with Tat-NR2B9c ameliorates Ab-mediated
toxicity in vitro.
Next, we tested in vivowhether APP23micewould also benefit
from treatment with Tat-NR2B9c. A single dose of this peptide
has previously been shown to confer virtually complete protec-
tion from excitotoxic damage in a rat model of stroke (Aarts
et al., 2002). First, we determined whether sufficient NR/
PSD-95 uncoupling was achieved by intracerebroventricular
(i.c.v.) Tat-NR2B9c treatment, using osmotic minipumps. We
delivered either Tat-NR2B9c or Tat-NR2BAA for 1 week and
then performed coIP with a PSD-95 antibody (Figure 6D). This
revealed a reduced NR/PSD-95 interaction upon Tat-NR2B9c,
but not Tat-NR2BAA, treatment. The level of reduction was
similar to that found in Dtau74 and tau/ brains (Figure 6D).
Sufficient uptake of peptides by the brain was further confirmed
by protection from PTZ-induced seizures by Tat-NR2b9c, but
not Tat-NR2BAA (Figure 6E). Next, we implanted minipumpsCell 142, 387–397, August 6, 2010 ª2010 Elsevier Inc. 393
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Figure 7. Simplified Scheme of the
Proposed Mechanism Underlying Reduced
Excitotoxicity in Dtau74 and tau/ Mice
Compared to the Wild-Type
(A) Postsynaptic NMDA receptors (NRs) are het-
eromeric complexes predominantly formed by
subunits NR1, NR2A, and NR2B. The Src kinase
Fyn localizes to the postsynapse in a tau-depen-
dent manner and associates with the postsynaptic
density (PSD; gray box), where it phosphorylates
(P) the NR subunit NR2b at Y1472 in the extreme
carboxy terminus. This phosphorylation facilitates
the interaction of NRs with the scaffolding protein
PSD-95. This interaction increases the stability of
NRs within the PSD and couples NRs to excito-
toxic downstream signaling (skull). NR-mediated
currents (ESPC trace), however, do not depend
on this NR/PSD-95 interaction. Whether tau is
associated with the PSD via Fyn or another inter-
action partner remains to be elucidated.
(B) In Dtau74 mice, Dtau is excluded from entering dendrites. Since Fyn interacts with Dtau (red bar) in the cell body of neurons, it is therefore trapped and less
localized to dendrites. Also, phosphorylation of NR2b and the interaction of NRs and PSD-95 are markedly reduced. Hence, excitotoxic downstream signaling is
uncoupled from NRs and their stability within the PSD is reduced. As NR-mediated currents are not dependent on this interaction, they are not affected.
(C) As forDtau74 mice, in tau/mice, tau-dependent localization of Fyn to the postsynapse is also markedly reduced. NR2b phosphorylation and the interaction
of NRs and PSD-95 are decreased. Thus, excitotoxic downstream signaling is uncoupled fromNRs, and their stability within the PSD is reduced. Again, NR-medi-
ated currents are not affected.into 6-week-old APP23 mice for i.c.v. delivery of artificial cere-
brospinal fluid (aCSF), with and without Tat-NR2B9c or Tat-
NR2BAA (Figure 6F). Mice in the aCSF and Tat-NR2BAA control
groups died frequently (7 of 11 and 4 of 9, respectively), whereas
only 1 of 17 mice died in the Tat-NR2B9c group (Figure 6E).
Finally, we tested whether Tat-NR2B9c-treatment has long-
term effects on memory in APP23 mice. The T maze revealed
comparable memory deficits in age-matched aCSF-treated
and untreated APP23 mice (Figure 6F). However, treatment
with Tat-NR2B9c resulted in a significantly improved perfor-
mance. Thus, perturbing NR/PSD-95 interaction is sufficient
to prevent premature lethality and memory deficits in APP23
mice.
DISCUSSION
Dendritic Localization of Fyn Is Tau-Dependent
Our data reveal a dendritic function of the ‘‘axonal’’ protein tau, in
targeting the kinase Fyn to the dendrite (Figure 7). We also found
an association of tau with the PSD complex by using coIP, PSD
purification, and immunohistochemistry with enhanced antigen
retrieval. It is important to note that levels of tau in the dendritic
compartment are much lower than in axons, suggesting that
under physiological conditions amajor function of tau is in axonal
MT stabilization and regulation of MT-dependent processes
(Dixit et al., 2008; Weingarten et al., 1975). Here, we show that
the additional role of tau in dendrites becomes pivotal in disease,
in particular in mediating early Ab toxicity.
In both Dtau74 and tau/ mice, dendritic targeting of Fyn is
significantly reduced, as revealed by immunohistochemistry
and synaptosomal purification and confirmed in primary
neurons. In Dtau74 mice, this is due to a competition of Dtau
with endogenous tau in the interaction with Fyn. Both the abun-
dance of Dtau in the cell body and its exclusion from dendrites394 Cell 142, 387–397, August 6, 2010 ª2010 Elsevier Inc.result in ‘‘trapping’’ of Fyn in the soma. Tau/ mice, in compar-
ison, show a similar accumulation of Fyn, suggesting that post-
synaptic Fyn targeting requires tau. This difference in mediating
aberrant sorting of Fyn between Dtau74 and tau/ mice
(Figure 7) may explain the additive effects on seizure suscepti-
bility and survival in Dtau.tau/ crosses. Reduced levels of
postsynaptic Fyn in Dtau74 and tau/ mice are associated
with reduced phosphorylation of the Fyn-substrate NR2b at
Y1472. Consistent with a critical role of Y1472 phosphorylation
in facilitating the interaction of NRs with PSD-95 (Rong et al.,
2001), this complex is reduced and destabilized in Dtau74 and
tau/ brains. Whether the Fyn-mediated stabilization of NR/
PSD-95 complexes in the PSD under physiological conditions
involves a direct interaction with tau and what the exact mecha-
nism(s) of tau-mediated dendritic Fyn localization are remains to
be established.
In a rat model of stroke, targeted disruption of the NR/PSD-95
interaction prevented excitotoxic damage and reduced the
lesion size (Aarts et al., 2002). Consistent with this, reduced
NR/PSD-95 complexes in Dtau74 and tau/ mice were associ-
ated with a reduced susceptibility to excitotoxicity. Interestingly,
NR-mediated currents were not affected in Dtau74 and tau/
mice, which is in line with normal synaptic activity upon treat-
ment with Tat-NR2B9c (Aarts et al., 2002). Normal NR-mediated
currents in Dtau74 and tau/ mice may be explained by
reduced, but not totally depleted, synaptic Fyn in Dtau74 and
tau/ mice, comparable to the situation in heterozygous fyn-
deficient mice that have no overt deficits (Yagi et al., 1993), while
in homozygous fyn-deficient mice these are pronounced (Grant
et al., 1992).
Dtau and tau/ Prevent Deficits of APP23 Mice
Excitotoxicity is increasingly recognized as a mechanism of how
Ab exerts toxicity in AD. Accordingly, we found that crossing
of Dtau74 and tau/ mice, both characterized by reduced
susceptibility to excitotoxicity, with Ab-forming APP23 mice
ameliorated premature mortality and memory deficits of APP23
mice. In contrast, early lethality was more pronounced in
APP23 mice crossed with pR5. Similarly, tau deficiency or Dtau
expression conferred protection from Ab-induced toxicity in
primary neuronal cultures. However, Ab levels and plaque forma-
tion, as well as endogenous tau phosphorylation (in APP23.D
tau74), were comparable in APP23 mice, suggesting an alterna-
tive mechanism for protection. Interestingly, in APP23 mice we
found both increased postsynaptic Fyn and Y1472 phosphoryla-
tion of NR2b that was completely reverted in APP23.Dtau74 and
APP23.tau/ mice. Further reduction of post-synaptic Fyn in
APP23.Dtau74.tau/ mice suggests additional tau-indepen-
dentmechanisms in dendritic Fyn localization, which are partially
competed with by Dtau. Consistent with a role for Fyn in Ab
pathology, Fyn transgenic mice present with seizures and
premature mortality (Kojima et al., 1998). This is exacerbated in
Fyn/APPmut double-transgenic mice (Chin et al., 2004). More-
over, APP-associated mortality is reduced on a fyn/ back-
ground (Chin et al., 2004). Hence, our findings in APP23.Dtau74
and APP23.tau/ mice are consistent with previous data (Chin
et al., 2005; Chin et al., 2004). Furthermore, they are in line
with the recent observation that crossing of PDAPP mice onto
a tau/ background reverses Ab-associated defects (Roberson
et al., 2007).
Mechanistically, our data suggest that stable NR/PSD-95
complex formation is required for Ab toxicity in APP23 mice.
This is likely to contribute to disease together with other tau-
dependent and -independent mechanisms of Ab toxicity. In
support of our findings, we used a tau/Fyn-independent
approach to disrupt this interaction, by delivering the Tat-
NR2B9c peptide to young APP23 mice. This peptide has been
shown to protect from excitotoxicity in vitro and in vivo.
We show specifically that perturbing the NR/PSD-95 interac-
tion with the Tat-NR2B9c peptide improves survival and
memory functions of APP23 mice. The data suggest that disrup-
tion of the NR/PSD-95 interaction is sufficient to prevent
Ab toxicity involving NR signaling. Remarkably, Tat-NR2B9c-
treated APP23 mice survived long term, suggesting that treat-
ment within a short therapeutic window is sufficient to prevent
lethality.
In summary, we reveal a dendritic role for the ‘‘axonal’’
protein tau in postsynaptic targeting of Fyn. This involves inter-
action of Fyn with the tau projection domain (Lee et al., 1998).
Accordingly, dominant negative effects of Dtau expression or
tau deficiency result in reduced postsynaptic Fyn, decreased
phosphorylation of its substrate NR2b and instability of NR/
PSD-95 complexes (in Dtau74 and tau/ mice). Importantly,
this additional function of tau appears to be pivotal for medi-
ating Ab toxicity, in that premature lethality, memory deficits,
and seizure susceptibility of APP23 mice were mitigated in
APP23.Dtau74 and APP23.tau/ mice. Hence, reduction of
tau levels or targeting of tau-dependent mechanisms, such as
the Fyn-mediated interaction of NRs and PSD-95, are suitable
strategies in the treatment of AD and related disorders, high-
lighting tau as an attractive drug target, in addition to Ab
(Ashe, 2007).EXPERIMENTAL PROCEDURES
Animals
APP23 and pR5 transgenic and tau/ mice have been generated previously
(Go¨tz et al., 2001a; Sturchler-Pierrat et al., 1997; Tucker et al., 2001). The
generation of Dtau74 mice is described in the Extended Experimental Proce-
dures. Two- to three-month-old mice were analyzed in age- and sex-matched
groups, unless stated otherwise. All animal experiments were approved by the
Animal Ethics Committee of the University of Sydney.
Histology, Western Blotting, IP, and Synaptosome Preparation
Detailed protocols are provided in the Extended Experimental Procedures.
Electrophysiology
Electrophysiological recording were done in acute hippocampal slices
obtained from 4- to 8-week-old wild-type, Dtau74, tau/, and Dtau74.tau/
mice as described in detail in the Extended Experimental Procedures.
Experimental Seizures
Seizures were induced by intraperitoneal (i.p.) injection of (50 mg/kg body
weight) pentylenetetrazole (PTZ; Sigma) as described (Roberson et al.,
2007). Where indicated, mice were injected i.p. with (0.1 mg/kg body weight)
MK801 (Sigma) 30 min prior to PTZ administration. Mice were video moni-
tored, and seizure severity was rated by an independent, blinded person, as
follows: 0, no seizures; 1, immobility; 2, tail extension; 3, forelimb clonus; 4,
generalized clonus; 5, bouncing seizures; 6, full extension; and 7, death.
i.c.v. Treatment with Osmotic Pumps
Six-week-old APP23 and WT mice were anesthetised with ketamine/xylazine,
and i.c.v. delivery cannulas (Alzet; brain infusion kit #3 with one spacer) were
implanted with a stereotaxic frame (KOPF Instruments) at the following
coordinates according to the bregma: AP, 0.25 mm; ML, 1 mm; and DV,
2.5 mm. Osmotic mini pumps (Alzet; model #1004) were filled with aCSF
(Alzet) with and without Tat-NR2B9c or Tat-NR2BAA peptide (750 mM) and
equilibrated in 0.9% NaCl at 37C for 48 hr. They were attached to the i.c.v.
cannula tubing and subcutaneously implanted at the back. After 28 days,
the pumps were replaced with a second batch of pumps via a small skin inci-
sion for another 28 days. Then, they were removed and the tubing was ligated.
Statistics
Statistics was done with the Prizm 4 software (GraphPad) with Student’s t or
two-way ANOVA test. Values are given as mean ± standard error.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
four figures and can be found with this article online at doi:10.1016/j.cell.
2010.06.036.
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